UCB Announces $5 Billion Investment in US Biologics Manufacturing Facility, Creating 300 Jobs

UCB is investing $5 billion in a new biologics manufacturing facility in the US, creating 300 direct high-skilled jobs and over 500 construction jobs. The facility will support the company's growth drivers and future pipeline, reinforcing its commitment to innovation, sustainable healthcare, and economic contribution. The investment is expected to generate significant value across communities through increased economic activity, partnerships, and job creation.

Title: UCB Announces Major Investment in U.S. Biologics Manufacturing Facility

June 13, 2025 — UCB, a global biopharmaceutical company, has announced a significant investment in a new biologics manufacturing facility in the United States. The project, valued at approximately $5 billion, is expected to create around 300 direct high-skilled jobs and more than 500 construction jobs. This investment underscores UCB's commitment to innovation, sustainable healthcare, and economic contribution in the U.S. market.

The new facility will support UCB's growth drivers and future pipeline, reinforcing the company's strategic ambition to serve its growing number of patients in the U.S. and strengthen its global manufacturing capacity. The investment includes scaling up partnerships with U.S. Contract Manufacturing Organizations (CMO) to ensure the support for the production of its growth drivers and future pipeline.

Since 2017, UCB's U.S. workforce has expanded by 73%, reaching around 2,000 employees, supported by $4.5 billion in acquisitions and capital investments. Over this period, UCB has achieved 15 FDA approvals or indication expansions, delivering meaningful advances in care for people living with severe diseases.

Jean-Christophe Tellier, CEO of UCB, stated, "This investment reflects our growing impact in the U.S. and our ambition to bring our forthcoming pipeline to patients around the world. By expanding our biologics manufacturing footprint, we're not only reinforcing our global supply chain—we're also contributing to the vitality of biomedical innovation, high-skilled jobs, and long-term economic impact in the U.S."

The new facility is expected to create around 300 permanent, highly skilled direct jobs in biologics manufacturing and more than 500 jobs during construction. UCB is currently undertaking a comprehensive feasibility study to determine the ideal U.S. location, focusing on regions with strong talent pipelines and innovation ecosystems.

This latest investment will not only support future medicine delivery but also generate significant value across communities through increased economic activity, partnerships, and job creation.

References:
[1] https://www.prnewswire.com/news-releases/ucb-announces-major-us-investment-to-expand-biologics-manufacturing-capacity-302480298.html
[2] https://www.bioprocessintl.com/facilities-capacity/cytiva-outlines-1-6bn-facility-investment-plans-through-2028